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Abstract
Purpose—Telephone disclosure of genetic test results can improve access to services. To date, 
studies of its impact have focused on return of Mendelian risk information, principally hereditary 
cancer syndromes.
Methods—In a multisite trial of Alzheimer’s disease genetic risk disclosure, asymptomatic 
adults were randomized to receive test results in-person or via telephone. Primary analyses 
examined patient outcomes 12 months after disclosure.
Results—Data from 257 participants showed that telephone disclosure occurred 7.4 days sooner 
and were 30% shorter, on average, than in-person disclosure (both p<0.001). Anxiety and 
depression scores were well below cutoffs for clinical concern across protocols. Comparing 
telephone and in-person disclosure protocols, 99% CIs of mean differences were within non-
inferiority margins on scales assessing anxiety, depression, and test-related distress, but 
inconclusive about positive impact. No differences were observed on measures of recall and 
subjective impact. Sub-analyses supported non-inferiority on all outcomes among APOE ε4-
negative participants. Sub-analyses were inconclusive for APOE ε4-positive participants, although 
mean anxiety and depression scores were still well below cutoffs for clinical concern.
Conclusion—Telephone disclosure of APOE results and risk for Alzheimer’s disease is 
generally safe and helps providers meet demands for services, even when results identify an 
increased risk for disease.
Keywords
Alzheimer’s disease; APOE; genetics; genomics; risk assessment; personalized medicine; 
information recall; telephone; genetic test results
INTRODUCTION
Face-to-face disclosure of genetic test results has been a long-standing practice,1 but the 
demand for services is outpacing the capacity of most clinics.2,3 Some individuals, 
particularly those in rural areas, find it challenging to meet with genetic service providers in 
person.4 To expedite timely disclosure of genetic test results to as many patients as possible, 
genetic specialists are increasingly providing results via telephone.5–7
Analyses of telephone disclosure to date are encouraging. Many patients prefer it to in-
person or mailed disclosure,8 and studies of its use during testing for hereditary cancer 
syndromes have shown comparable levels of patient understanding and satisfaction after 
telephone and in-person disclosure.9–13 Two randomized trials demonstrated non-inferiority 
of telephone disclosure on a variety of outcomes, showing that differences from in-person 
disclosure on scales of test-related distress, knowledge and overall satisfaction were not 
clinically meaningful.13–15 To date, however, studies of telephone disclosure have almost 
exclusively focused on hereditary cancer syndromes.
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Genetic testing to determine risk of Alzheimer’s disease (AD) provides a rich context for 
examining disclosure of genetic risk information for a common, complex conditions. The ε4 
allele of apolipoprotein E (APOE) is a prevalent and robust genetic risk factor for AD.16 but 
is neither necessary nor sufficient for disease. The Risk Evaluation and Education for 
Alzheimer’s Disease (REVEAL) Study is a series of multi-center randomized clinical trials 
that have examined the impact of AD genetic susceptibility testing using APOE genotyping. 
Previous analyses have shown that testing does not increase risks for psychological harm, 
even among individuals who are ε4-positive;17–19 and that the majority of participants 
accurately recall test results.20–22 Here, we report on the third REVEAL Study trial, 
hypothesizing that mean scores on a variety of patient outcomes would be no worse 
following telephone disclosure than following in-person disclosure.
METHODS
Study Population
We recruited cognitively normal adults using mailings to research registries, postings on 
institutional research web sites, referrals from collaborating physicians, and advertisements 
in local newspapers at study sites in Boston, Cleveland, Ann Arbor, and Washington, DC. 
We established targets to enroll equal numbers of adults over and under the age of 60, equal 
numbers of men and women, and a 1:3 ratio of subjects with zero and one AD-affected first-
degree relative (FDR), respectively. Screening per prespecified criteria was conducted 
initially by phone, and again more extensively by study clinicians during the first in-person 
appointment. Individuals were excluded if they had histories suggestive of hereditary AD (2 
or more AD-affected FDRs, family members with average AD onset under age 60), or 
scored below an education-adjusted 87 on the Modified Mini-Mental State Examination 
(3MS).23 We also screened out individuals with severe anxiety or depression per validated 
scales (defined below).
Study Design
A multidisciplinary team designed the study protocol, approved by institutional review 
boards at each study site and an independent external Ethics and Safety Board, and the study 
was registered at ClinicalTrials.gov (NCT00462917). The study protocol, statistical code, 
and data set are available from the authors upon request. Briefly, participants who completed 
a phone interview and written questionnaire received educational materials developed in a 
prior trial.17 Participants then met with a genetic counselor and provided a blood sample for 
APOE genotyping at a CLIA-certified laboratory. Participants provided informed consent by 
telephone prior to the initial phone interview, then again in person prior to the blood draw 
for genotyping. Disclosure sessions were scheduled at the discretion of individual sites. 
Genetic counselors disclosed APOE genotypes and AD risk information using a script that 
allowed participants to raise any questions or concerns they had. Numeric estimates of 
lifetime (cumulative incidence from birth to the age of 85 years. Range: 6% to 73%) and 
remaining risk for AD (cumulative incidence from current age to the age of 85 years) were 
accompanied by graphs of AD risk curves. The methods for calculating risk estimates and 
generating risk curves are published previously.24,25 A written summary of the risk 
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assessments were given to participants at the end of in-person disclosure sessions or mailed 
to participants following telephone disclosure.
A 2×2 factorial design determined whether participants received risk assessments in-person 
or via telephone, and whether or not participants additionally learned about an association 
between the ε4 allele of APOE and an increased risk for coronary artery disease, reported 
separately.19 Participants were randomized equally within strata, in blocks of size four, into 
“AD-only, in-person disclosure,” “AD-only, telephone disclosure,” “AD+CAD, in-person 
disclosure,” and “AD+CAD, telephone disclosure” arms. Randomization strata were defined 
by site, age (<60 vs ≥60), family history of AD, and gender. Serially-numbered envelopes 
concealed randomization statuses until the initial in-person visit. Randomization occurred 
prior to this appointment, which included confirmation of study eligibility, to allow consent 
forms customized to AD+CAD or AD-only randomization status to be mailed before in-
person review.
Outcomes were assessed through questionnaires administered 6 weeks, 6 months, and 12 
months after genotype and genetic risk disclosure. At the end of 6 week and 6 month follow-
up appointments and after surveys were completed, genetic counselors verbally reminded 
participants about their genotypes, risk estimates, and about APOE-CAD associations (if 
appropriate). For safety purposes, subjects whose anxiety or depression scores exceeded 
standard cutoffs for severe mood disorders or increased by more than 15 points from 
baseline were immediately interviewed by a genetic counselor.
Measures
Outcome Variables—Outcomes of interest are bolded and included anxiety, depression, 
test-related distress (assessed via two scales), positive impact, recall of results, and 
subjective impact at 6 weeks, 6 months, and 1 year after results disclosure, all assessed via 
self-administered questionnaires. Outcomes were selected based on concerns about how 
telephone disclosure may impact the communication of information.26
Psychological outcomes included measures of general anxiety, general depression, two 
scales assessing test-related distress, and positive impact. Anxiety was assessed using the 
Beck Anxiety Inventory (BAI),27 with scores ranging from 0–63 (>8: mild, >15: moderate, 
>25: severe). Depression was assessed using the 20-item Center for Epidemiological 
Studies-Depression Scale (CES-D),28 with scores ranging from 0–60 (>10: mild, >16: 
moderate, >26: severe).29 Test-related distress was assessed with the 15-item Impact of 
Event Scale (IES),30 with scores ranging from 0–75 (≥20: significant distress) and the 
distress subscale of Impact of Genetic Testing for Alzheimer’s disease instrument (IGT-AD 
distress), with higher scores on a 0–60 scale indicating more negative feelings.31 Positive 
impact was assessed with the positive subscale of the IGT-AD, where items were reverse-
scored such that lower scores on a 0–20 scale indicated more positive feelings.31
Recall of results was measured as the sum of correct responses when participants report 
back their results: 1) number of AD risk increasing alleles, 2) genotype, 3) lifetime AD risk 
estimate, and 4) remaining AD risk estimate. The risk allele and genotype items were 
assessed via multiple choice and included a “don’t remember” option. Risk estimate items 
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asked participants to provide their lifetime and remaining risk percentages and were 
considered correct if responses were within 5% of communicated results, as used in prior 
analyses.20–22 Item prompts encouraged participants to provide their best guess if they did 
not remember their estimate. An additional open-ended item asked, “What other disease did 
we tell you is associated with the APOE gene?”, but is analyzed separately from other recall 
items because it was administered only to participants randomized to AD+CAD disclosure.
Subjective impact was assessed by asking participants to rate the “overall impact” that the 
risk information had on a 5-point scale (“very negative” to “very positive”).
Other Variables—Participants reported demographic information during the phone 
interview and on the baseline written questionnaire. Personal and family history of AD, 
cardiovascular disease, and other medical conditions were assessed during the blood draw 
appointment, as was numeracy using a validated scale with scores ranging from 0–8 based 
on the number of items a participant answers correctly.32 Participants also completed a 
validated 4-item version of a scale assessing self-reported comfort with numbers, with 
scores ranging from 1 to 6 based on mean ratings across items.33 After disclosure sessions, 
genetic counselors completed a chart note and indicated if topics discussed addressed any 12 
issues, including the accuracy of results or preventive measures. Disclosure session length 
was calculated in minutes by comparing the start and finish times recorded on chart notes.
Statistical Analysis
A priori goals to enroll 280 participants and achieve 256 disclosures were set to power 
original hypotheses to compare disclosure of AD and CAD risk information against 
disclosure of only AD risk information, the main focus of the trial.19 Here we focused on the 
comparison between telephone and in-person disclosure. We used t-tests and chi-squared 
tests to compare demographics of the randomization arms and to analyze who dropped out 
after randomization. We used chi-squared tests to compare dropout rates of study arms after 
randomization, but before results disclosure. We used t-tests of log-transformed times to 
compare how long after the blood draw that disclosure sessions occurred and to compare the 
length of disclosure sessions, and used chi-squared tests to determine whether topics 
discussed during disclosure sessions varied by randomization status.
Telephone disclosure was intended to streamline service delivery rather than improve patient 
responses. Therefore, we used a non-inferiority framework to test whether outcomes were no 
worse after telephone disclosure than after in-person disclosure. We asserted non-inferiority 
of telephone disclosure on measures of anxiety, depression, test-related distress, and positive 
impact if the upper limit for the confidence interval (CI) of mean differences between 
telephone and in-person randomization arms was below a predefined margin.34
We used longitudinal analyses for all outcomes, including all observed data and imputing 
data for the few missing observations. We used generalized linear models fit with 
generalized estimating equations. For analyses of BAI, CES D, IES, IGT-AD distress and 
IGT-AD positive scores, we used a log link and Gamma distribution to compare outcomes 
by phone versus in-person randomization status, as these measures were very skewed and 
had a high proportion with zeros. For analyses of ordinal variables, recall was dichotomized 
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to compare full recall (all items recalled correctly) against less than full recall, and 
subjective impact was dichotomized to compare responses of “very” and “somewhat 
positive” against responses of “neutral” and “somewhat” or “very negative.” Analyses of 
recall and subjective impact used a logit link and binomial distribution. We used an 
autoregressive working correlation structure with robust standard errors to account for the 
repeated measures within participant. A value of one was added to BAI, CES-D, IES, and 
IGT measures to shift their distributions away from zero. Models included terms for phone 
or in-person disclosure randomization status, time as a categorical variable, interaction 
between time and randomization arm, and the corresponding baseline psychological measure 
where applicable. Analyses on the IGT-AD distress subscale included a term to account for 
an interaction between telephone/in-person randomization status and AD-only/AD+CAD 
randomization status (p<0.05). Additional analyses were conducted to compare arms in 
APOE ε4-positive and APOE ε4-negative participants, as well as to further adjust for age, 
gender, education, race, family history of AD, AD+CAD or AD-only information disclosure, 
numeracy and self-reported comfort in analyses of information recall.20 We also conducted 
analyses where missing data were not imputed to minimize potential biases in non-
inferiority analyses.34 These adjusted analyses and available case analyses are omitted from 
this report, because unadjusted models using imputed data were considered conservative in 
comparison (i.e., we report non-inferiority only when it was demonstrated in all analyses). 
We used contrasts to compare randomization arms at specific time points and overall for a 
time-averaged comparison.
Consistent with analyses of prior REVEAL Study trials,17,19 outcomes at 12 months were 
considered primary, while outcomes at 6 months and 6 weeks were considered secondary. 
Data for AD+CAD and AD-only disclosure arms were pooled in analyses because 
interactions between AD-only/AD+CAD randomization status and in-person/telephone 
disclosure randomization status were not observed (p-values for two-way tests of interaction 
between the two treatment arms and three-way interactions between the treatment arms and 
time were all greater than 0.05 except for analyses of IGT-AD distress scores, as noted 
earlier). The margin of non-inferiority for BAI, CES-D, and IES scores was 5 points, as used 
in prior REVEAL Study trials, indicative of medium to large effect sizes (Cohen’s d = 1.03, 
0.64, and 0.66, respectively).17,18 This criterion was a more conservative margin than 5 to 
10-point definitions of “clinically meaningful” differences used in other studies that are 
based on the intervals between cutoffs for minimal, mild, moderate, and severe anxiety and 
depression.35–37 For IGT-AD scores where prior studies have not identified a meaningful 
difference, we set margins following the strategy used in a related non-inferiority analysis:13 
three points, representing a shift from “sometimes” to “never” on a single item and 
indicative of medium effect sizes (Cohen’s d = 0.43 and 0.48 for distress and positive 
subscales, respectively). Non-inferiority margins were not established for recall or subjective 
impact measures.
We used 99% CIs for primary analyses (12 month outcomes) to account for testing of seven 
outcomes (anxiety, depression, test-related distress per the IES and IGT-AD, positive impact, 
and recall of results). These CIs are more conservative than a Bonferroni correction, given 
guidelines to use one-sided tests.34 To be consistent across outcomes, we used 99% CIs on 
all secondary analyses. Additional secondary analyses used 99% CIs of 2-group tests of 
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proportions to compare recall rates on individual recall items by randomization status and 
McNemar tests to compare whether participants were more likely to recall specific items 
more often than others.
Analyses included only participants receiving genetic risk information (genotype data for 
participants who provided blood but dropped out of the study before the disclosure session 
was destroyed per the IRB-approved protocol). We assumed data were missing at random 
and imputed missing values using multiple imputation (Markov Chain Monte Carlo 
procedures with 40 imputed data sets). All analyses were conducted using SAS, version 9.3 
(SAS Institute, Cary, North Carolina).
RESULTS
Of 290 randomized participants, 257 (88.6%) received genetic risk disclosure (Figure 1) 
with no observed differences in dropout rates between telephone and in-person disclosure 
arms (∆=0.1%, p=0.99). Twenty four randomized participants withdrew before disclosure 
for the following non-exclusive reasons: concerns about potential emotional responses (8), 
study demands (4), personal or family health problems (4), concerns about privacy, 
confidentiality, or discrimination (4), lack of AD prevention options (3), moved (2), no 
longer interested (1), concerns about test limitations (1), and desire for higher remuneration 
(1). One participant passed away, and four were lost to follow-up. Four others did not meet 
eligibility criteria due to low 3MS scores, high CES-D scores, questionable family history of 
AD, and failure to attend study appointments.
Demographic characteristics of participants who received genetic risk information did not 
vary by disclosure method (Table 1) and were similar to those of the second REVEAL Study 
trial except for the inclusion of individuals without an AD-affected FDR.17 On average, 
telephone disclosure occurred 7.4 days sooner than in-person disclosure (27.8 vs 35.2 days 
after the blood draw, respectively; p=0.002). Disclosure sessions ranged from 6 to 40 
minutes in length for telephone disclosure and 5 to 50 minutes in length for in-person 
disclosure, and telephone disclosure sessions were 6.6 minutes shorter than in-person 
disclosure sessions, on average (p<0.001). Disclosure session chart notes showed that 
participants were more likely to discuss preventive options during in-person disclosure than 
telephone disclosure (26% vs 14%, respectively, p=0.015). Disclosure sessions did not vary 
in length by APOE status (p=0.15 in bivariate analyses, p=0.16 in analyses controlling for 
telephone/in-person randomization status).
One year after disclosure and across randomization arms, participants remembered 3.0 of 4 
items correctly, on average, and scored well below cutoffs for clinical concern on anxiety 
and depression scales (see Table 2). Overall, 24% of participants receiving in-person 
disclosure and 23% of participants receiving telephone disclosure reported moderate anxiety, 
depression, or test-related distress at one or more follow-up time points, with no differences 
observed by disclosure method (p=0.61). The majority of participants (65.6%) rated the 
subjective impact of their risk assessment as positive, while 7.9% rated it negative and 
26.5% rated it neutral. Mean scores on measures of general anxiety and depression were 
well below cutoffs for clinical concern at all time points, and positive impact scores 
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increased over time (p<0.001). With the exception of IGT-AD positive scores, CIs for mean 
differences between telephone and in-person disclosure arms were below prespecified 
margins of non-inferiority for all scales at all time points in analyses that were not stratified 
by APOE status (Table 2) and in analyses of ε4-negative participants (Table 3). However, 
analyses in ε4-positive participants supported non-inferiority of telephone disclosure at 12 
months only on anxiety. Furthermore, upper limits of 99% CIs exceed margins for non-
inferiority on IES and IGT-AD distress scores at the six-week and six-month time points, 
and upper limits of 99% CIs exceeded margins for non-inferiority on the IGT-AD positive 
scale at six weeks.
Additional analyses suggested that telephone disclosure outperformed in-person disclosure 
on some components of recalling results (Table 4). Participants were more likely to correctly 
recall lifetime AD risk estimates at 6 months (∆=17.6%, 99%CI: 4.6% to 30.6%) and 12 
months (∆=15.8%, 99%CI: 2.1% to 29.6%) after telephone disclosure compared to in-person 
disclosure. Independent of disclosure method or genotype, recall scores were higher at 6 
weeks than at 6 months (∆=0.3, p<0.001) or 12 months (∆=0.4, p<0.001). At 12 months, ε4-
positive participants were more likely than ε4-negative participants to correctly recall their 
genotype (74.0% vs 56.3%, p=0.008). Across genotypes and randomization arms, data for 
individual recall items were highly correlated (r>0.57 in all pairwise comparisons), although 
participants were less likely to recall their specific genotypes compared to the number of risk 
alleles they had or their lifetime or remaining AD risk estimates (all pairwise comparisons 
p<0.001). Participants who did not accurately recall numeric AD risk estimates tended to 
provide estimates lower than what were reported during disclosure sessions: 64.2% of 
participants with inaccurate lifetime risk recall provided estimates lower than those reported, 
and 61.5% of participants with inaccurate remaining risk recall provided estimates lower 
than those reported.
DISCUSSION
On average, telephone disclosure of genetic risk information about AD was safe and did not 
increase psychological risks. Although we were unable to demonstrate statistical non-
inferiority for some outcomes within the subset of individuals who learned that they were 
APOE ε4-positive, their mean anxiety and depression scores were still well below cutoffs 
for clinical concern. These findings are notable because risk disclosure for AD has been 
used as an example of potentially distressing information, given the lack of proven 
preventative strategies. Anticipation of telephone disclosure did not appear to affect 
participants’ willingness to receive a genetic risk assessment, and wait times for disclosure 
sessions were shorter when results were disclosed by telephone, with the disclosure sessions 
themselves briefer than in-person disclosure sessions.
These findings are encouraging given that many genetic service providers are already 
disclosing test results via phone. Telephone disclosure is a long-standing practice in prenatal 
settings given time-sensitive implications for pregnancies, and it is now in wider use in other 
settings when results suggest no carrier or disease risks.6 Our data are consistent with 
findings from research on hereditary breast and ovarian cancer syndromes, showing that 
telephone disclosure does not increase risks for misremembering results or psychological 
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harms.11–13 In fact, telephone disclosure seemed to improve participants’ abilities to retain 
numeric risk estimates. This improvement may be because participants received information 
at two distinct time points, first during phone disclosure sessions, then again when 
participants received the information via mail. The time savings noted in our study were also 
comparable to the time savings observed in the BRCA1/2 telephone disclosure studies, 
although our overall session lengths in our trial were often shorter. The comparably greater 
time needed for disclosing BRCA1/2 test results may be attributable to time needed to 
discuss medical management decisions and implications for other family members.
Genotype-specific analyses of our data suggest that genetic service providers should be 
mindful of the potential for additional distress when disclosing results indicating increased 
risk via telephone. Non-inferiority was supported on all psychological outcomes except 
positive impact at 12 months among ε4-negative participants. However, non-inferiority of 
telephone disclosure was not demonstrated on some 12 month outcomes among ε4-positive 
participants. Possible explanations for this include the reduced ability of providers to read 
non-verbal cues since genetic counselors are trained to use and respond to body language to 
encourage patients to engage with information and to reduce discomfort.1 Telephone 
conversations are often more succinct than those that are face-to-face,38 and participants or 
genetic counselors in our study may have felt pressure to be parsimonious about what they 
addressed on the phone. Our telephone disclosure protocol did not allow participants to view 
reports while genetic counselors were discussing results, and made it difficult for 
participants to have a support person present during disclosure. Whatever the reasons, 
genetic service providers may need to be selective about when to disclose potentially 
distressing genetic risk information via telephone. Pre-disclosure anxiety and depression 
scores are the strongest predictors of post-disclosure outcomes. Therefore, telephone 
disclosure of ε4-positive results to individuals with significant anxiety or depression may not 
be optimal.18 One strategy that many clinics have already implemented is to have an in-
person consultation following telephone disclosure when patients have an increased genetic 
risk.10,11
Our study also evaluated recall of genetic test results one year after disclosure. Typically, 
studies have examined recall immediately after or within 1–2 months of disclosure. Even 
after reiterating information 6 weeks and 6 months after disclosure, we observed a steady 
decrease in recall over time. Of note, this trial had higher percentages of correct recall, even 
at six weeks, than the first REVEAL Study trial,21 perhaps due to the study population (e.g., 
more self-referred participants, individuals without AD-affected FDRs) or due to 
modifications in disclosure protocols. Data from this trial also reinforced findings from prior 
trials, showing that individuals who did not recall their lifetime and remaining risks correctly 
tended to underestimate their risk estimates, and that ε4-positive individuals were more 
likely to correctly recall their genotype than ε4-negative individuals.21 It is likely that 
individuals who were APOE ε4-positive saw a greater need to remember this information 
given their increased risk status.
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Limitations
Study participants had higher education and numeracy than the general population. 
Measures were self-administered, and we could not ascertain whether participants reviewed 
written summaries during recall assessments. For questions about lifetime and remaining 
AD risk estimates, participants were not given a “don’t remember” option, and participants 
may have been categorized as correctly recalling information after guessing. Results may not 
generalize to situations in which results might be disclosed by healthcare providers without 
genetics expertise. Post-hoc calculations based on the differences that we observed 
suggested that we only had approximately 17% power to confirm noninferiority among ε4-
positive participants on the IES, where differences were closest to noninferiority margins; 
and that we would need approximately 106 ε4-positive participants in each arm to achieve 
80% power. Our sample size also limited our ability to examine interactions between 
telephone disclosure and factors such as education and race.9 Our study did not assess 
potential benefits such as increasing access to testing, decreasing costs to patients, or 
opening up clinic slots.5,9 We also did not assess the impact of telephone disclosure on 
outcomes such as risk perceptions, health behaviors and advance planning, although we have 
reported on the impact of genetic risk disclosure for AD on these outcomes previously.
19,39–41
 Such analyses may be important given differences we observed between 
randomization arms in the likelihood of discussing prevention during disclosure sessions.
Conclusion
Important challenges still remain to telephone disclosure of genetic test results, including 
reimbursement policies that encourage in-person visits, but payers are increasingly willing to 
pay for telephone consultations,42 and companies are now offering telephone genetic 
counseling. In addition, efforts are already underway to improve the timely disclosure of test 
results using patient portals associated with electronic medical record systems, mailing 
negative results, web-based disclosure, and video conferencing. AD risk disclosure is likely 
to grow in importance as prediction algorithms improve by incorporating polygenic, clinical, 
and environmental risk factors.43 Our results regarding telephone disclosure are encouraging 
given the need for efficient and effective approaches for conveying risk information and test 
results for common, complex diseases.
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Figure 1. 
Enrollment flow chart
* Second randomization occurred at this point to determine whether participants received 
only AD risk information or whether they additionally received risk information about CAD.
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Table 1
Characteristics of subjects who received genetic risk disclosure
Randomization Arm
Characteristic
In-Person
(n=132)
Telephone
(n=125) P
Age: yrs
  Mean ± SD 58.2 ± 12.9 58.1 ± 13.0 0.95
  Range 21–83 22–82
Female sex: n (%) 73 (55) 68 (54) 0.88
African American race: n (%) 21 (16) 17 (14) 0.60
Education: yrs
    Mean ± SD 16.6 ± 2.4 17.0 ± 2.2 0.18
    Range 10–20 12–20
Currently married: n (%) 78 (59) 75 (60) 0.88
Site: n (%) 0.99
    Boston 40 (30) 38 (30)
    Cleveland 32 (25) 32 (25)
    Ann Arbor, MI 35 (27) 33 (26)
    Washington, DC 25 (19) 22 (18)
Parent or sibling with AD: n (%) 89 (67) 89 (71) 0.51
Pleiotropic disclosure: n (%) 64 (48) 55 (44) 0.47
Has ε4 allele: n (%) 0.86
    One copy 37 (28) 34 (27)
    Two copies 7 (5) 5 (4)
Numeracy: mean ± SD 7.1 ± 1.3 7.4 ± 1.3 0.06
Comfort with numbers: mean ± SD 4.5 ± 1.0 4.7 ± 0.9 0.10
BAI score: mean ± SD 3.4 ± 3.5 3.6 ± 3.5 0.55
CES-D score: mean ± SD 5.9 ± 5.0 5.5 ± 5.2 0.56
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Table 2
Mean outcome scores by randomization group and time after APOE genotype disclosure.*
Variable
In person
(n=132)
Phone
(n=125)
Difference
(99% CI)
12-mo outcomes
  BAI 3.6 3.5 −0.2 (−1.5 to 1.2)
  CES-D 6.2 7.4 1.1 (−1.2 to 3.4)
  IES 3.1 3.7 0.5 (−2.1 to 3.1)
  IGT distress 4.4 4.2 −0.3 (−2.7 to 2.2)
  IGT positive 13.1 14.3 1.2 (−1.3 to 3.8)
  Full recall 37.3% 50.1% 1.7 (0.8 to 3.4)†
  Positive subjective impact 68.7% 63.8% 0.8 (0.4 to 1.7)†
6-mo outcomes
  BAI 3.1 2.8 −0.3 (−1.4 to 0.9)
  CES-D 5.3 6.1 0.8 (−1.2 to 2.8)
  IES 3.8 4.0 0.2 (−2.4 to 2.7)
  IGT distress 4.1 4.6 0.5 (−1.7 to 2.7)
  IGT positive 11.3 11.7 0.4 (−2.0 to 2.8)
  Full recall 46.6% 55.4% 1.4 (0.7 to 2.8)†
  Positive subjective impact 71.8% 64.7% 0.7 (0.4 to 1.5)†
6-wk outcomes
  BAI 2.9 3.1 0.3 (−0.7 to 1.3)
  CES-D 4.8 6.5 1.7 (−0.2 to 3.6)
  IES 3.9 4.4 0.5 (−2.1 to 3.1)
  IGT distress 4.6 5.1 0.5 (−1.8 to 2.7)
  IGT positive 9.2 10.4 1.1 (−1.1 to 3.4)
  Full recall 61.6% 61.9% 1.0 (0.5 to 2.0)†
  Positive subjective impact 63.9% 56.8% 0.7 (0.4 to 1.5)†
Time-averaged outcomes
  BAI 3.2 3.1 0.0 (−0.9 to 0.9)
  CES-D 5.4 6.6 1.0 (−0.4 to 2.8)
  IES 3.6 4.0 0.4 (−1.9 to 2.7)
  IGT distress 4.4 4.6 0.2 (−1.9 to 2.3)
  IGT positive 11.1 12.0 0.9 (−1.1 to 3.0)
  Full recall 44.4% 52.4% 1.4 (0.8 to 2.4)†
  Positive subjective impact 65.5% 58.3% 0.8 (0.4 to 1.3)†
*Scores were estimated using generalized estimating equations with log link and γ distribution for continuous measures and with logit link and 
binomial distribution for dichotomized measures, with adjustment for corresponding baseline values (where applicable) and the genetic counselor 
providing disclosure.
†
Differences for dichotomized outcomes, full recall and positive subjective impact, represent odds ratios (i.e, the odds of full recall or positive 
subjective impact following telephone disclosure compared to in-person disclosure).
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Table 4
Percentages recalling specific genetic test results correctly by disclosure method and time point, adjusted for 
APOE genotype.
Information
In-Person
(n=132)
Telephone
(n=125)
Difference
(99% CI)
1 Year
  Number of risk alleles 80.5% 79.8% −0.7% (−13.5% to 12.2%)
    Presence/absence of a risk allele 81.9% 83.8% 1.9% (−10.2% to 14.0%)
  Genotype 59.3% 65.0% 5.7% (−9.9% to 21.2%)
  Lifetime AD risk estimate (±5%) 66.4% 82.2% 15.8% (2.1% to 29.6%)
  Remaining AD risk estimate (±5%) 71.6% 83.6% 12.0% (−1.2% to 25.3%)
  Additional disease association* 78.1% 87.3% 9.2% (−8.5% to 26.8%)
6 Months
  Number of risk alleles 85.8% 83.8% −2.0% (−13.5% to 9.6%)
    Presence/absence of a risk allele 86.8% 85.6% −1.2% (−12.3% to 9.9%)
  Genotype 61.4% 66.0% 4.6% (−10.8% to 20.1%)
  Lifetime AD risk estimate (±5%) 69.1% 86.7% 17.6% (4.6% to 30.6%)
  Remaining AD risk estimate (±5%) 77.0% 80.3% 3.3% (−9.9% to 16.4%)
  Additional disease association* 84.4% 87.3% 2.9% (−13.6% to 19.4%)
6 Weeks
  Number of risk alleles 86.9% 82.4% −4.5% (−16.0% to 7.1%)
    Presence/absence of a risk allele 90.3% 86.4% −3.9% (−14.2% to 6.4%)
  Genotype 70.9% 79.2% 8.3% (−5.5% to 22.2%)
  Lifetime AD risk estimate (±5%) 82.9% 86.0% 3.2% (−8.5% to 14.8%)
  Remaining AD risk estimate (±5%) 86.3% 91.9% 5.6% (−4.3% to 15.6%)
  Additional disease association* 78.1% 83.6% 5.5% (−13.0% to 24.0%)
*
Item was administered to participants randomized to AD+CAD disclosure, only.
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